Please assess the completion status of the following clinical trial:

Trial Title: The Dual Antiplatelet Therapy Study (DAPT Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (Enrollment):~1. Subject is \> 18 years of age.~2. Subjects undergoing percutaneous intervention with stent deployment (or has w/in 24 hours).~3. Subjects without known contraindication to dual antiplatelet therapy for at least 30 months after enrollment and stent implantation.~4. The subject has consented to participate and has authorized the collection and release of his medical information by signing the Patient Informed Consent Form. The informed consent will be valid for the duration of the trial or until the subject withdraws.~Inclusion Criterion (Randomization at 12 months):~1. Subject, at 12 months, is free from death, MI, stroke, repeat coronary revascularization, major bleeding, and stent thrombosis and has been compliant with dual antiplatelet therapy following stent implantation.~Exclusion Criteria (Enrollment):~1. Index procedure stent placement with stent diameter \<2.25 mm or \>4.0 mm.~2. Pregnant women.~3. Planned surgery necessitating discontinuation of antiplatelet therapy within the 30 months following enrollment.~4. Current medical condition with a life expectancy of less than 3 years.~5. Concurrent enrollment in another device or drug study whose protocol specifically excludes concurrent enrollment or that involves blinded placement of a DES or BMS other than those included as DAPT Study devices. The subject may only be enrolled in the DAPT Study once.~6. Subjects on warfarin or similar anticoagulant therapy.~7. Subjects with hypersensitivity or allergies to one of the drugs or components indicated in the Instructions for Use for the device implanted.~8. Subjects unable to give informed consent.~9. Subject treated with both DES and BMS during the index procedure.~Exclusion Criteria (Randomization at 12 months):~1. Pregnant women.~2. Subject switched thienopyridine type or dose within 6 months prior to randomization.~3. Percutaneous coronary intervention or cardiac surgery between 6 weeks post index procedure and randomization.~4. Planned surgery necessitating discontinuation of antiplatelet therapy within the 21 months following randomization.~5. Current medical condition with a life expectancy of less than 3 years.~6. Subjects on warfarin or similar anticoagulant therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 12m DAPT Study Arm (Type: PLACEBO_COMPARATOR): This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
- 30m DAPT Study Arm (Type: ACTIVE_COMPARATOR): This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine treatment in addition to aspirin.

Based on this trial design, predict the completion outcome and termination type (if applicable).